ライフサイエンスコーパス: nesiritide

1 -51 mL/h with placebo and 110+/-56 mL/h with nesiritide.

2 will permit effective and appropriate use of nesiritide.

3 pamine (2 microg/kg per minute) nor low-dose nesiritide (0.005 mug/kg per minute without bolus) enhan

4 Subjects were randomized to receive nesiritide (0.01 microg/kg/min with or without a 2-micro

5 short-term outcome data from patients given nesiritide (0.015 or 0.03 microg/kg per min) with a subg

6 = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.1

7 .1% and 12.8%, respectively; odds ratio with nesiritide 1.12; confidence interval, 0.95-1.32; P=0.19)

8 nts then received an intravenous infusion of nesiritide (2 microg/kg bolus followed by 0.01 microg/kg

9 Patients received nesiritide (2 microg/kg IV bolus followed by an infusion

10 t of the hospital within 30 days of surgery (nesiritide, 20 [minimum to maximum, 0-24]; milrinone, 18

11 Seventy-five patients were enrolled (39 nesiritide, 36 placebo).

12 t effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296

13 Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has be

14 otrope-based controls, respectively), as did nesiritide administered at any dose up to 0.06 microg x

15 This study was designed to determine whether nesiritide, administered for acute decompensated congest

16 rine output was 2,280 (1,550, 3,280) ml with nesiritide and 2,200 (1,550, 3,200) ml with placebo (p =

17 lantation, but intraoperatively the doses of nesiritide and anesthetics must be adjusted because of a

18 HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure), 7,141 patie

19 isk of in-hospital mortality was similar for nesiritide and nitroglycerin.

20 Use of nesiritide and other intravenous vasoactive therapy amon

21 Nesiritide and placebo data were compared by repeated-me

22 on during hospitalization was similar in the nesiritide and placebo group (14.1% and 12.8%, respectiv

23 or for the entire 24-hour period between the nesiritide and placebo study days.

24 de equivalent) was 80 (40, 140) mg with both nesiritide and placebo.

25 None of the interaction terms between nesiritide and predictors affected the urine output pred

26 rmalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart

27 ritide) and B-type natriuretic peptide (BNP; nesiritide) are used to treat congestive heart failure.

28 ides and thus explain the ineffectiveness of nesiritide as a cardiac failure medication.

29 We investigated the renal effects of nesiritide as treatment for ADHF.

30 Patients randomly assigned to nesiritide, as compared with those assigned to placebo,

31 Nesiritide (B-type natriuretic peptide) is a new intrave

32 On the basis of these results, nesiritide cannot be recommended for routine use in the

33 The corresponding values for nesiritide compared with milrinone and dobutamine were 0

34 The adjusted OR for nesiritide compared with nitroglycerin was 0.94 (95% CI

35 r 24 h showed greater PEFR improvement after nesiritide compared with placebo (p = 0.048).

36 Nesiritide did not affect renal function in patients wit

37 The addition of nesiritide did not change urine output.

38 Nesiritide did not improve renal function in patients wi

39 Nesiritide did not increase urine output in patients wit

40 Compared to dobutamine, both nesiritide doses were administered for a shorter total d

41 tion, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal funct

42 Nesiritide exerts coronary vasodilator effects on both t

43 with recombinant brain natriuretic peptide (nesiritide) failed to prove it.

44 receptor blockers for chronic heart failure, nesiritide for acute heart failure, and cytochrome P-450

45 o open-label therapy with standard agents or nesiritide for up to seven days.

46 Patients in the nesiritide group had an increase of plasma B-type natriu

47 rom any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (abso

48 ontrast, renal function was preserved in the nesiritide group with no significant change in estimated

49 end of the 24-hour infusion, but not in the nesiritide group.

50 end toward decreased readmissions in the two nesiritide groups (8% and 11%, respectively, vs. 20% in

51 Six-month mortality was lower in the nesiritide groups.

52 Nesiritide had a greater effect than placebo on PEFR, an

53 ts who received intravenous nitroglycerin or nesiritide had lower in-hospital mortality than those tr

54 le-blind, placebo-controlled clinical trial, nesiritide had no impact on renal function in patients w

55 Nesiritide had no interaction on the relationship betwee

56 Similarly, low-dose nesiritide had no significant effect on 72-hour cumulati

57 Nesiritide has been shown in controlled trials in conges

58 Treatment with nesiritide has shown fewer arrhythmias and a lower morta

59 A new vasodilator, nesiritide, has been demonstrated to improve hemodynamic

60 this study was to further define the role of nesiritide (human b-type natriuretic peptide) in the the

61 Recombinant B-type natriuretic peptide (nesiritide), identical to the principle natriuretic pept

62 with decompensated congestive heart failure, nesiritide improves hemodynamic function and clinical st

63 for use of nitroprusside, nitroglycerin, or nesiritide in addition to diuretics to achieve hemodynam

64 To provide a context for Acute Study of Nesiritide in Decompensated Heart Failure (ASCEND-HF) tr

65 rom Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), w

66 (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure [ASCEND-HF]; N

67 nal Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial.

68 al (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) included 4205

69 HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomi

70 HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was a global

71 al (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was used to p

72 al (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

73 he efficacy and safety of different doses of nesiritide in heart failure therapy are warranted.

74 olus dose and 6-h infusion administration of nesiritide in HF patients.

75 (A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Fa

76 We investigated the clinical use of nesiritide in such patients.

77 addition, any patient admitted who received nesiritide in the absence of a primary or secondary hear

78 ports have shown the advantageous effects of nesiritide in the early post-bypass period.

79 Nesiritide in the setting of CABG with CPB is associated

80 The use of nesiritide, in the absence of an ICD-9 heart failure cod

81 However, whether or not nesiritide increases diuresis in ADHF patients is unknow

82 This study sought to determine if nesiritide increases diuresis in congestive heart failur

83 ed to double-blind treatment with placebo or nesiritide (infused at a rate of 0.015 or 0.030 microg p

84 ardial oxygen uptake decreased 8% during the nesiritide infusion (P=0.043).

85 In the efficacy trial, at six hours, nesiritide infusion at rates of 0.015 and 0.030 microg p

86 effect of dopamine (interaction P=0.001) and nesiritide (interaction P=0.039) on urine volume varied

87 Nesiritide is a promising new tool, and its application,

88 Although nesiritide is approved for the treatment of acute decomp

89 Nesiritide is approved in the United States for early re

90 hat perioperative administration of low dose nesiritide is biologically active and decreases plasma c

91 In cardiac surgery, nesiritide is mainly administered to patients awaiting h

92 ng the potential renal-preserving effects of nesiritide is mixed, and further studies on the efficacy

93 Nesiritide is useful for the treatment of decompensated

94 Even low-dose nesiritide (< or =0.015 microg x kg(-1) x min(-1)) signi

95 od and Drug Administration-approved doses of nesiritide (< or =0.03 microg x kg(-1) x min(-1)) signif

96 s suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal f

97 Treatment of decompensated CHF with nesiritide may lead to lower healthcare costs and reduce

98 , and renal effects of natriuretic peptides, nesiritide might be useful in the management of patients

99 pose of this study was to determine the role nesiritide might play in patients with left ventricular

100 jects, 35, 36, and 35 were randomized to the nesiritide, milrinone, and placebo groups, respectively,

101 es in which patients received nitroglycerin, nesiritide, milrinone, or dobutamine were identified and

102 mary Fontan surgery were assigned to receive nesiritide, milrinone, or placebo.

103 The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared

104 andomized to placebo (n=20) or i.v. low dose nesiritide (n=20; 0.005 microg/Kg/min) for 24 hours star

105 sustained beneficial hemodynamic effects of nesiritide observed in this study support its use as a f

106 Rapid de-adoption of nesiritide occurred following 2 publications suggesting

107 spital hypotension included randomization to nesiritide (odds ratio, 1.98; 95% confidence interval [C

108 e also tested for treatment interaction with nesiritide on 30-day outcomes and the association betwee

109 We examined the effects of nesiritide on GFR (measured by iothalamate clearance), r

110 We studied the effects of nesiritide on renal function during hospitalization for

111 results have been reported on the effects of nesiritide on renal function in patients with acute deco

112 Our purpose was to evaluate the impact of nesiritide on renal function in patients with acute deco

113 there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of deconge

114 There were minimal effects of nesiritide on survival, future hospitalizations, and sym

115 The effects of intravenous nesiritide on the human coronary vasculature have not be

116 regression models to identify the impact of nesiritide on urine output and the factors associated wi

117 The effect of dopamine and nesiritide on weight change, sodium excretion, and incid

118 mpared with placebo, empirical perioperative nesiritide or milrinone infusions are not associated wit

119 We sought to determine whether empirical nesiritide or milrinone would improve the early postoper

120 1 patients were randomized to receive either nesiritide or placebo and creatinine was recorded in 570

121 rt failure (ADHF) were randomized to receive nesiritide or placebo for 24 to 168 h, in addition to st

122 d with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to

123 preserved ejection fraction (EF) to receive nesiritide or placebo in addition to standard care.

124 e female; no significant differences between nesiritide or placebo patients existed.

125 ith anticipated use of CPB to receive either nesiritide or placebo, in addition to usual care, for 24

126 eline, 1, 6, and 24 h after randomization to nesiritide or placebo.

127 Nesiritide produced significant reductions in pulmonary

128 Nesiritide, recombinant human B-type natriuretic peptide

129 re between January and August 2001 (prior to nesiritide release) and January 2004 to December 2005 (b

130 Nesiritide significantly increases the risk of worsening

131 pen, 1:1 allocation ratio to the dopamine or nesiritide strategy.

132 Nesiritide (synthetic human brain natriuretic peptide) i

133 Among those patients treated with nesiritide, the mean duration of treatment changed minim

134 us, dyspnea, and fatigue were sustained with nesiritide therapy for up to seven days and were similar

135 luation of Cardiac Ectopy with Dobutamine or Nesiritide Therapy) trial were analyzed.

136 osimendan, and istaroxime) and neuropeptide (nesiritide) therapy will be reviewed.

137 With nesiritide, there were no differences in clinical outcom

138 nine and blood urea nitrogen were similar in nesiritide-treated and placebo-treated patients (P=0.20

139 In addition, nesiritide-treated patients had a shorter hospital stay

140 ar to operate via coronary artery disease or nesiritide treatment (P>0.05); and the signal was still

141 Nesiritide use decreased from a peak of 16.6% (2351 of 1

142 ure) was a global randomized trial comparing nesiritide versus placebo among patients hospitalized fo

143 From an open-label randomized study of nesiritide versus standard care (SC) in patients with CH

144 f death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, -

145 ring placebo was 40.9+/-25.9 mL/min and with nesiritide was 40.9+/-25.8.

146 Compared with placebo, nesiritide was associated with a significantly attenuate

147 Nesiritide was not associated with an increase or a decr

148 As such, synthetic BNP, nesiritide, was approved for the treatment of acutely de

149 Nesiritide, which is the recombinant equivalent of B-typ

150 Randomized clinical trials comparing nesiritide with either placebo or active control for ADH

151 one or placebo, patients assigned to receive nesiritide would have improved early postoperative outco